Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice

Rafat A. Siddiqui1*, Samira Hassan1, Kevin A. Harvey1, Tamkeen Rasool1, Tapas Das2, Pradip Mukerji2 and Stephen DeMichele2

1Methodist Research Institute, Clarian Health Partners, 1800 N. Capitol Avenue, Indianapolis, IN 46202, USA
2Research and Development, Abbott Nutrition, Abbott Laboratories, Columbus, OH 43215, USA

(Received 17 October 2008 – Revised 18 March 2009 – Accepted 19 March 2009 – First published online 27 April 2009)

Muscle wasting or cachexia is caused by accelerated muscle protein breakdown via the ubiquitin–proteasome complex. We investigated the effect of curcumin c3 complex (curcumin c3) on attenuation of muscle proteolysis using in vitro and in vivo models. Our in vitro data indicate that curcumin c3 as low as 0·50 μg/ml was very effective in significantly inhibiting (30%; P<0·05) tyrosine release from human skeletal muscle cells, which reached a maximum level of inhibition of 60% (P<0·05) at 2·5 μg/ml. Curcumin c3 at 2·5 μg/ml also inhibited chymotrypsin-like 20S proteasome activity in these cells by 25% (P<0·05). For in vivo studies, we induced progressive muscle wasting in mice by implanting the MAC16 colon tumour. The in vivo data indicate that low doses of curcumin c3 (100 mg/kg body weight) was able to prevent weight loss in mice bearing MAC16 tumours whereas higher doses of curcumin c3 (250 mg/kg body weight) resulted in approximately 25% (P<0·05) weight gain as compared with the placebo-treated animals. Additionally, the effect of curcumin c3 on preventing and/or reversing cachexia was also evident by gains in the weight of the gastrocnemius muscle (30–58%; P<0·05) and with the increased size of the muscle fibres (30–65%; P<0·05). Furthermore, curcumin inhibited proteasome complex activity and variably reduced expression of muscle-specific ubiquitin ligases: atrogen-1/muscle atrophy F-box (MAFbx) and muscle RING finger 1 (MURF-1). In conclusion, oral curcumin c3 may be an effective adjuvant therapy against cachexia.

MAC16 tumours: Cachexia: Curcumin: Proteasomes: Muscle wasting

Cachexia is defined as the progressive wasting of body tissues that primarily affects muscle and adipose tissue(1–3). Patients suffering from sepsis, trauma, AIDS and many types of cancer exhibit cachexia(4–10). All cancer patients exhibit some degree of cachexia, and it is one of the most important factors leading to early morbidity and mortality, accounting for up to 30% of all deaths(11). It is particularly more pronounced in pancreatic and head–neck cancers(6,12–14). Studies during the last 10 years have concluded that muscle wasting is primarily caused by accelerated muscle protein breakdown via the ubiquitin–proteasome complex(15). Expression in muscle of two ubiquitin ligases, namely mouse atrophy gene-1 (atrogin-1) (also described as the muscle atrophy F-box; MAFbx) and the muscle RING finger 1 (MURF-1)(16,17), is up-regulated in various animal models of muscle atrophy, including fasting, cancer, sepsis, disuse, denervation, diabetes and uraemia(16–20). Similarly, muscle wasting situations in humans, including immobilisation(21), acute quadriplegic myopathy and neurogenic atrophy(22), are also accompanied with up-regulated MAFbx/atrogin-1 and MURF-1 expression.

Various inflammatory cytokines, including TNFα, interferon γ, IL-6, leukaemia inhibitory factor, and mediators, including proteolysis-inducing factor and lipid mobilising factor, are known to play a role in the development of cachexia(23). Currently, therapies aimed at neutralising these cytokines or mediators have had only limited success(24). Furthermore, anorexia is often accompanied by cachexia; however, refeeding a balanced diet does not reverse the progression of cachexia(25). Recently, attempts have been made to supplement diets with nutrients that specifically inhibit muscle proteolysis(26). One such promising supplement is curcumin (1,7-bis(4-hydroxy-3-methoxyphenil)1, 6-heptadiene-3,5-dione), which is present in turmeric. Curcumin has anti-inflammatory, antioxidant, anticarcinogenic, anti-diabeticogenic, antibacterial, antiviral and free radical-scavenging properties(27–31). The pharmacology and putative anticancer properties of curcumin have been extensively reviewed(32). Recent studies indicate that curcumin may also possess anti-protolytic properties. For example, curcumin is reported to inhibit proteasome activity in HeLa cells(33), as well as attenuate the proteolysis-inducing factor-induced increase in proteasome activity in the muscle tissues of tumour-bearing mice(34). The intraperitoneal administration of curcumin daily for four consecutive days before a lipopolysaccharide

Abbreviations: LPS, lipopolysaccharide; MAFbx, muscle atrophy F-box; MURF-1, muscle RING finger 1; SkBM, Skeletal Muscle Cell Basal Medium; Tris, 2-amino-2-hydroxymethyl-propane-1,3-diol.
* Corresponding author: Dr Rafat A. Siddiqui, fax +1 317 962 6941, email rsiddiqu@clarian.org
(LPS) injection in mice blunted LPS stimulation of atrogen-1/MAFbx mRNA expression in gastrocnemius and extensor digitorum longus muscle of mice. Curcumin has been shown to increase the rate and extent of muscle regeneration after trauma. In contrast to these studies, intraperitoneal administration of curcumin (20 μg/kg body weight) has been ineffective in preventing muscle wasting or changes in the body weight of rats bearing the highly cachectic Yoshida AH-130 ascites hepatoma. Similarly, curcumin treatment by mouth at higher dose levels (150 and 300 mg/kg body weight) was shown to be ineffective in preventing loss of body weight in mice bearing the MAC16 colon tumour. It is, therefore, not clear why a compound that has potential inhibitory activities against protein degradation in vitro failed to reverse cachexia in experimental models. Low curcumin absorption and hence bioavailability have been suggested as the primary reasons for the failure of curcumin. We hypothesised that this failure of curcumin in those studies was due to using an animal model that exhibited a drastic body-weight loss (20 % over 5 d) as well as short treatment duration (4–5 d). To test our hypothesis, we used a standardised patent curcumin extract, and reinvestigated its effect on proteolysis in human skeletal muscle cells, and also treated cachectic animals that were gradually losing body weight (20 % over 21 d) for a longer duration (21 d).

Experimental methods

Cell cultures

Proliferating human skeletal myoblast cells (Cambrex Bio Science, Walkersville, MA, USA) were cultured in Clonetics Skeletal Muscle Cell Basal Medium (SkBM®; Cambrex Bio Science) supplemented with bovine serum albumin, bovine fetuin, insulin, dexamethasone, recombinant human epidermal growth factor and gentamycin sulfate with amphoterin B (all supplied with SkBM®), accord- ing to the manufacturer’s instructions. Cells were not differentia ted into myotubules under these conditions. Cells were subcultured when they were approximately 70 % confluent.

Validation of curcumin c3 complex

The present study was performed using curcumin c3 complex, a standardised preparation (Sabinsa, Piscataway, NJ, USA) which has been used extensively in human safety trials. For validation, the composition of curcumin c3 complex was analysed by a reversed-phase HPLC method using an Agilent 1100 HPLC system (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with an Agilent 1100 diode-array detector, an Agilent 1100 autosampler system and an Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150 mm; 5 μm). The mobile phase consisted of A (15 % acetonitrile in 0.05 M-KH2PO4; pH 2.9) and B (80 % acetonitrile in distilled water) solvents as follows: 0 % solvent B from 0–5 min; 0–80 % solvent B from 5–30 min (linear gradient); 100 % solvent B from 30–1–35 min; 0 % solvent B from 35–1–45 min (end) at a flow rate of 0.5 ml/min. The detection wavelengths were 260 and 428 nm. Chromato graphic peaks were identified by comparing retention times of samples with those of standards (curcumin, bisdemethoxy curcumin, demethoxycurcumin) as described.

Cytotoxic effects of curcumin

Cells (1 × 10^5 per well) were seeded in a ninety-six-well plate overnight and then treated with varying concentrations of curcumin (100 U/ml and 100 μg/ml) and 10 μg/ml of recombinant human Bio Science) supplemented with bovine serum albumin, after trauma. In contrast to these studies, intraperitoneal administration of curcumin (20 μg/kg body weight) has been ineffective in preventing muscle wasting or changes in the body weight of rats bearing the highly cachectic Yoshida AH-130 ascites hepatoma. Similarly, curcumin treatment by mouth at higher dose levels (150 and 300 mg/kg body weight) was shown to be ineffective in preventing loss of body weight in mice bearing the MAC16 colon tumour. We failed to reverse cachexia in experimental models. Low curcumin absorption and hence bioavailability have been suggested as the primary reasons for the failure of curcumin. We hypothesised that this failure of curcumin in those studies was due to using an animal model that exhibited a drastic body-weight loss (20 % over 5 d) as well as short treatment duration (4–5 d). To test our hypothesis, we used a standardised patent curcumin extract, and reinvestigated its effect on proteolysis in human skeletal muscle cells, and also treated cachectic animals that were gradually losing body weight (20 % over 21 d) for a longer duration (21 d).

In vitro protein degradation

Protein degradation in response to serum starvation was assayed as described. Briefly, skeletal muscle cells were plated in twenty-four-well tissue culture plates for 24 h, then rinsed with serum-free SkBM® culture media, and finally labelled under serum-free conditions with L-[3,5-3H]tyrosine (1905.3 GBq (51.50 Ci)/mmol; 0.036996 MBq (1 μCi/ml in each well) for another 24 h. Labelled monolayers were washed three times with serum-free SkBM® containing 50 μM-cycloheximide and 2 mM-unlabelled tyrosine and then incubated in the same media (2 ml) for 48 h in the presence or absence of curcumin. A sample of the media was then removed (750 μl) for determining radioactive tyrosine release, mixed with 5 ml of ScintiVerse (Fisher Scientific, Hanover Park, IL, USA) and the radioactivity was quantified using a Beckman L6000 liquid scintillation counter (Beckman Coulter, Inc., Fullerton, CA, USA). Inhibition of tyrosine release in the media by curcumin c3 was calculated from tyrosine release in the absence of curcumin (control, 100 %) after correcting for subtraction of background counts.

Animal model of cachexia

The murine MAC16 colon tumour model for inducing cachexia in mice was established as previously described. Murine MAC16 tumour cells originally derived in Dr Michael Tisdale’s laboratory (Aston University, Birmingham, UK) were kindly provided by Dr Constance Monitto (John Hopkins Hospital, Baltimore, MD, USA). Cells were initially maintained in culture in Roswell Park Memorial Institute (RPMI) 1640 medium with l-glutamine (GIBCO BRL; Life Technolo gies, Rockville, MD, USA) containing 12 % fetal bovine serum (HyClone, Logan, UT, USA) and penicillin–streptomycin (100 U/ml and 100 μg/ml, respectively) in a humidified atmosphere with 5 % CO2 at 37°C. For tumour induction, 200 μl of MAC16 cells (5 × 10^5/ml in PBS) were injected subcutaneously in the lower back of Hsd:Athymic nude–nu male mice (aged 6–7 weeks, average body weight 26-71 (SD 1.31) g; Harlan Laboratories, Indianapolis, IN, USA).
Once the tumour was palpable the body weight of the animals and progression of tumour growth were recorded every day post–tumour implantation (PI) using a digital caliper (Fisher Scientific, Pittsburgh, PA, USA). Animals that exhibited a loss of 5–7 % of initial body weight (10–12 d PI) were randomised into treatment groups (five animals per group). Mice were orally administered daily with placebo vehicle (200 µl olive oil) or 100 mg/kg body weight or 250 mg/kg body weight of curcumin c3 (in 200 µl olive oil) as described(35). Animals were given a standard laboratory non–purified diet (LabDiet, catalogue no. 5001; Ted’s Feed, Indianapolis, IN, USA) and water ad libitum. The diet consists of 24 % proteins, 10–7 % fats, 48 % carbohydrates and 5 % fibres. Upon completion of the study, mice were euthanised by inhalation of the anaesthetic gas isoflurane. Mice were skinned and tumours removed to measure the carcass body weight. Hindquarters were removed and weighed. Gastrocnemius muscles from both legs were removed, weighed and quickly frozen in liquid N2. Thigh muscles were used for tissue sections. Tissue specimens were stored at −80 °C for biochemical analysis. The protocol for these studies was approved by the Methodist Research Institute’s Animal Research Committee and strictly followed the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, revised 1996).

Muscle histology

Transverse serial sections of quadriceps muscle (10 µm) were prepared using a cryostat (Leica CM1900; Leica Microsystems, Bannockburn, IL, USA). The sections were stained using haematoxylin and eosin staining (Sigma Chemical Co., St Louis, MO, USA). Images of rectus femoris muscle sections were recorded using a digital camera (mounted on a microscope) as described(36). The surface area of individual muscle bundles (representing mixed fibre types) were measured using ImagePro software (Cybernetics, Silver Spring, MD, USA).

Proteasome assay

The effect of curcumin c3 on proteasome activity was assayed in both muscle extracts of MAC16 tumour-bearing mice as well as in serum-starved human skeletal muscle cells. Gastrocnemius muscles of mice were homogenised using a polytron homogeniser in 20 mM-2-amino-2-hydroxymethyl-ethane glycol tetraacetic acid) using a polytron homogeniser. The homogenate was solubilised in 1:1 ratios with lysis buffer (20 mM-Tris-HCl (pH 7.4), 137 mM-NaCl, 100 mM-NaF, 2 mM-Na2VO4, 10 % glycerol, 1 % nonidet P-40, 2 mM-phenylmethylsulfonylfluoride, leupeptin (1 µg/ml), aprotonin (0.15 units/ml) and 2.5 mM-diisopropylphosphate) for 10 min on ice. The detergent-solubilised extracts were centrifuged to remove insoluble matter. After evaluating the protein content using a bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, USA), 15 µg of protein solubilised in Laemmli sample loading buffer was loaded onto each lane of a 4–12 % gradient SDS–polyacrylamide gel. Proteins were electrophoretically separated and transferred onto nitrocellulose membranes (Millipore Corporation, Bedford, MA, USA) for immuno-Western blot analysis. Blots were then incubated with anti-MAFbx (Oncogene Research Products, Calbiochem, San Diego, CA, USA) and anti-MURF-1 (Oncogene Research Products) primary antibodies (1:1000 dilution in Tris-buffered saline with Tween-20) according to the manufacturer’s specifications and proteins were detected using a peroxidase-conjugated secondary antibody (1:5000 dilution in Tris-buffered saline with Tween-20 containing 1 % bovine serum albumin) with an enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotechnology, Piscataway, NJ, USA). For reprobing, membranes were stripped in buffer consisting of 62.5 mM-Tris-HCl (pH 6.8), 2 % SDS and 100 mM-β-mercaptoethanol for 30 min at 50 °C followed by six washes in Tris-buffered saline (pH 7.4) with 0.1 % Tween 20. To verify an equal distribution of protein loading, blots were re-probed with a peroxidase-conjugated glyceraldehyde-3-phosphate dehydrogenase antibody (1:1000 dilution in Tris-buffered saline with Tween-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The resolved proteins were quantified by densitometry using a Kodak Image Station (MM2000; Kodak, Rochester, NY, USA).

Statistical analysis

One-way ANOVA was used for overall comparisons across all treatment groups. Post hoc pairwise comparisons were performed using Tukey’s multiple-comparison test. Statistical analysis was completed using Minitab 14.2 (Minitab Inc., State College, PA, USA). Data were summarised by treatment group using mean and standard error. The Student’s t test was also used (as mentioned elsewhere) to determine differences between individual groups compared with control. A value of P<0.05 was considered statistically significant.

Results

Curcumin c3 composition

We tested the purity of curcumin c3 complex and found it to contain 73 % curcumin, 22 % desmethoxycurcumin and 4 % bis-desmethoxycurcumin as reported by the manufacturer. Treatment of curcumin c3 at 100 mg/kg body weight therefore contained 73 mg curcumin, 22 mg desmethoxycurcumin and 4 mg bis-desmethoxycurcumin/kg body weight, whereas treatments with 250 mg curcumin c3/kg body weight contained 182.5 mg curcumin, 55 mg desmethoxycurcumin and 10 mg bis-desmethoxycurcumin/kg body weight.
Curcumin c3 inhibits protein breakdown and chymotrysin-like 20S proteasome activity in skeletal muscle cells

In an initial screen, we investigated cytotoxic concentrations of curcumin c3 for human skeletal muscle cells. Curcumin c3 was well tolerated up to a concentration of 2.5 μg/ml. Concentrations over 2.5 μg/ml appeared to be toxic, causing total cell death at 5 μg/ml (data not shown). The subsequent experiments were therefore performed under non-toxic concentrations. Data shown in Fig. 1(a) demonstrate that curcumin c3 has a dose-dependent effect on protein degradation as assayed by tyrosine release during serum starvation. It is clear from the data that a curcumin c3 concentration as low as 0.50 μg/ml was very effective in significantly inhibiting (30%; \(P<0.05\)) tyrosine release, which reached a maximum level of inhibition of (60%; \(P<0.05\)) at 2.5 μg/ml. Consistent with this result, our data in Fig. 1(b) demonstrate that curcumin c3 at 2.5 μg/ml was able to inhibit chymotrysin-like proteasome 20S activity by 25% \(P<0.05\).

Curcumin c3 treatment prevents body-weight loss

Data presented in Fig. 2 indicate that placebo-treated tumour-bearing animals progressively lost body weight, reaching a total loss of approximately 18–20% at day 21. When treated at a lower dose of curcumin c3 (100 mg/kg body weight), MAC16-tumour-bearing animals effectively maintained their initial loss of 4–7% of body weight \(P<0.05\) compared with placebo. However, tumour-bearing animals treated with a higher dose of curcumin c3 (250 mg/kg body weight) initially resisted any loss of body weight during the first 10d treatment and then started gaining weight and were able to increase their weight by 8–10% from their initial body weight by day 21 \(P<0.05\) and by 25% \(P<0.05\) compared with placebo-treated tumour-bearing control. These animals achieved comparable body-weight gains to those of non-tumour-bearing placebo-treated animals (Fig. 2). Subtraction of the tumour’s weight from the animal’s weight at the end of the study (day 21 post-treatment) indicated that low and high doses of curcumin c3 treatment caused a net increase in body weight by 24% \(P<0.05\) and 35% \(P<0.05\), respectively, compared with that of placebo-treated animals (Table 1). The animals in all three groups did not exhibit significant differences in tumour weights at day 21 (Table 1). Moreover, the animals did not exhibit significant differences in average daily food intake before and after tumour implantation (Table 1).

Curcumin improves muscle characteristics

We next examined whether the increase in body weight in tumour-bearing animals on curcumin c3 treatment was due
to improvements in the animals’ muscle characteristics. Weights of gastrocnemius muscle were increased by 30% ($P<0.05$) and 58% ($P<0.05$) in low- and high-curcumin c3-treated animals, respectively, compared with those of placebo-treated animals (Table 1). Consistent with these observations, muscle fibre size was also increased, as depicted in Fig. 3(a). Quantification of these muscle fibres indicated that their size increased by 30% ($P<0.05$) and 65% ($P<0.05$) in low- and high-curcumin c3-treated animals, respectively, compared with that of placebo-treated animals (Fig. 3(b)). The weight of hindquarters was statistically not different in animals treated with low ($P<0.12$) and high ($P<0.06$) curcumin c3, compared with placebo-treated animals (Table 1).

### Curcumin c3 inhibits muscle proteolysis

We further examined whether improvements in muscle characteristics after curcumin c3 treatment was a result of curcumin c3’s effect on the proteasome pathway. Curcumin c3 treatment resulted in the inhibition of chymotrypsin-like proteasome 20S activity by 22–25% ($P<0.05$) as compared with placebo (Fig. 4(a)). However, there was no significant difference between low v. high curcumin c3 treatment. We further examined the expression of atrogin-1/MAFbx and MURF-1 expression through Western blot analysis (Fig. 4(b)). Expression of atrogin-1/MAFbx was reduced by 20–25% ($P=0.11$) in isolated gastrocnemius muscle on curcumin c3 treatment compared with that of controls (placebo treatment); however, expression of MURF-1 was reduced by 40–75% ($P=0.06$) on treatment with curcumin c3 (Fig. 4(c)). It is interesting to note that a significant difference ($P<0.05$) in the inhibition of MURF-1 expression was observed when animals treated with high doses of curcumin were directly compared with the control group using Student’s t test.

### Discussion

Our data indicate that a low dosage of curcumin c3 (100 mg/kg body weight) was able to prevent weight loss in mice bearing cachexia-inducing MAC16 tumours whereas a higher dosage at 250 mg/kg body weight resulted in weight gains compared with that of placebo-treated animals. These animals maintained body weight similar to normal non-tumour-bearing mice despite the presence of tumour. It is noticeable that tumour burdens in both curcumin- and placebo-treated animals were not statistically different ($P<0.67$); therefore, the effect of curcumin on body weight is independent of tumour burden. The effect of curcumin c3 on body-weight gain was also independent of food intake as there was no statistically significant difference between the food intake of control and curcumin c3-treated animals. Furthermore, the effects of curcumin c3 treatment on inhibiting and/or reversing cachexia in MAC16 tumour-bearing mice are also evident by weight gain in gastrocnemius muscle (30–58%), and increased size of muscle fibres (30–65%). It is interesting to note that the present

**Table 1. Effect of curcumin c3 treatment on MAC-16 tumour-bearing mice**

(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>Control (no treatment)</th>
<th>Curcumin c3 (100 mg/kg body weight)</th>
<th>Curcumin c3 (250 mg/kg body weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily food intake (g)†</td>
<td>2.17 ± 0.18</td>
<td>2.24 ± 0.14</td>
<td>2.45 ± 0.12</td>
</tr>
<tr>
<td>Tumour weight (g)</td>
<td>3.35 ± 0.72</td>
<td>2.59 ± 0.33</td>
<td>2.85 ± 0.68</td>
</tr>
<tr>
<td>Body weight – tumour weight (g)</td>
<td>17.53 ± 1.28</td>
<td>21.81 ± 1.55</td>
<td>23.85 ± 2.02</td>
</tr>
<tr>
<td>Hindquarters (g)</td>
<td>2.29 ± 0.12</td>
<td>2.63 ± 0.16</td>
<td>3.17 ± 0.30</td>
</tr>
<tr>
<td>Gastrocnemius muscle weight (g)</td>
<td>0.12 ± 0.01</td>
<td>0.15 ± 0.01</td>
<td>0.19 ± 0.02</td>
</tr>
</tbody>
</table>

* Mean values within a row with unlike superscript letters were significantly different ($P<0.05$).

* Analysed by ANOVA for at least five animals per group.

† The daily food intake of the non-tumour-bearing animals was 2.47 (SE 0.09) g.
results are not in agreement with previous studies on the effect of curcumin on the cachectic MAC16 mouse model\textsuperscript{(34)}. However, there are technical differences in the present study compared with previous studies\textsuperscript{(34)}. In previous studies, a drastic loss in muscle mass or body weight was induced by the tumours in a shorter period of time (20\% over 5 d)\textsuperscript{(34)}, while we established a gradual loss in body weight by implanting a smaller load of MAC16 cultured cells. This approach resulted in a slow body-weight loss totalling 18–20\% over 21 d. Furthermore, we used a different source

---

**Fig. 4.** Effect of curcumin c3 on 20S chymotrypsin-like proteasome activity and muscle atrophy F-box (MAFbx)/atrogen-1 and muscle RING finger 1 (MURF-1) expression in muscle. Gastrocnemius muscle homogenate was used to determine 20S chymotrypsin-like activity and MAFbx/atrogen-1 and MURF-1 expression at the end of the study (day 21 on curcumin treatment). (a) Chymotrypsin-like 20S proteasome activity in the supernatant fraction of muscle homogenates was determined using a kit (20S Proteasome Activity Kit; Boston Biochem, Cambridge, MA, USA). (b) The solubilised protein extracts of muscle homogenates were used to determine MAFbx/atrogen-1 and MURF-1 expression by Western blot analysis. Lanes 1, 2 and 7 represent MAC16–curcumin c3-treated mice (250 mg/kg body weight (BW)); lanes 3, 5 and 9 represent MAC16–curcumin c3-treated mice (100 mg/kg BW); lanes 4, 6 and 8 represent MAC16-untreated mice. (c) Quantification of protein expression (\(\beta\), MAFbx/atrogen-1; \(\mu\), MURF-1) was determined by densitometry analysis. Densities (arbitrary units) are shown underneath each band whereas the numbers in parentheses refer to densities normalised to the loading control (glyceraldehyde 3-phosphate dehydrogenase; GADPH). Values are the means for three experiments, with standard errors represented by vertical bars. The results were analysed using ANOVA. a,b,c Mean values with unlike letters were significantly different (\(P<0.05\)).
of curcumin, i.e. curcumin c3 complex, which has been exten-
sively used in human trials\(^{39–41}\). The composition of curcu-
mín extracts in the previous study was not reported; it is
therefore not clear if there were compositional differences in
our curcumin c3 complex from that used in previous studies.
It is possible that purity and compositional differences may
have contributed to the biological activity of the curcumin
c3 effects. Moreover, we suspended curcumin in olive oil,
whereas other studies used curcumin dissolved in dimethyl
sulfoxide and then diluted (100X) in PBS\(^{34}\). It is possible
that olive oil may serve as a better vehicle for curcumin c3
complex as it is hydrophobic in nature and provides improved
bioavailability compared with an aqueous vehicle such as PBS
used in the previous study. Lastly, the animals in the present
study were on curcumin c3 treatment for 21 d, whereas pre-
vious studies used a 4–5 d treatment\(^{38,37}\). Treatment over a
longer period of time with curcumin c3 might have overcome
the low bioavailability of curcumin in general. Several inves-
tigators have reported low plasma levels of curcumin and its
metabolites\(^{38,42}\). Recent studies demonstrate that curcumin
and its metabolites are cleared from plasma in rats within
2 h of oral treatment\(^{42}\). During the present investigation,
the concentration of curcumin was not measured because it
was not possible to withdraw blood from these mice on a
daily basis during the 21 d treatment. In our opinion, these fac-
tors, including the rate of body wasting, the unique patented
composition of curcumin c3 complex, its suspension in olive
oil and the duration of treatment might have facilitated the
efficacy of curcumin c3 complex.

The ubiquitin–proteasome pathway is the primary pathway
involved in protein catabolism and is felt to be the major
degradation pathway involved in various cachectic condi-
tions\(^{17,47–50}\). The ubiquitin–proteasome pathway is stimu-
lated by TNF, IL-1, interferon γ and other pro-inflammatory
mediators\(^{51–54}\). Pro-inflammatory cytokines and proteol-
ysis-inducing factor activate the ubiquitin–proteasome path-
way through the transcription factor NF-κB. We tested 20S
chymotrypsin-like activity of the ubiquitin–proteasome path-
way in muscle specimens of curcumin c3- or placebo-treated
animals. The present results indicate that chymotrypsin-like
activity of the 20S proteasome was significantly suppressed in mice treated with curcumin c3 compared with placebo-
treated mice. However, there was no difference on inhibition
of chymotrypsin-like activity between low and high doses of
curcumin c3 treatment. During the present investigation, we
did not examine the chymotrypsin-like activity of the 20S
proteasome in non-tumour-bearing muscle; it is therefore not
clear if the inhibition of chymotrypsin-like activity of the
20S proteasome reached a basal level on curcumin treatment.
Nevertheless, the present results are consistent with previous
findings where curcumin attenuated the proteolysis-inducing
factor-induced increase in the ‘chymotrypsin-like’ enzyme
activity of the 20S proteasome\(^{34}\).

Genes encoding for ligases (i.e. atrogin-1/MAFbx and
MURF-1) within the ubiquitin–proteasome pathway are
instrumental in the development of muscle atrophy\(^{17}\). For
example, the development of atrophy and muscle proteolysis
during sepsis is blocked by proteasome inhibitors\(^{55}\).
We tested the expression of atrogin-1/MAFbx and MURF-1 in
muscles isolated from curcumin- and placebo-treated animals.
Expression of MURF-1 was inhibited in the muscle of animals
treated with high doses of curcumin c3, but there was no sig-
nificant effect on atrogin-1/MAFbx expression. It is not clear
from these results if curcumin inhibited proteolysis through
atrogin-1/MAFbx- and MURF-1-mediated pathways. It is
possible that other cellular pathways, including pathways for
protein synthesis, may be involved in mediating curcumin
effects on body-weight regulation. Several pathways have
been proposed for the effect of curcumin c3 in directly regu-
lating protein degradation and synthesis. For example,
expression of MAFbx/atrogin-1 and MURF-1 under stressing
conditions is regulated by unphosphorylated forkhead box tran-
scription factors class O (FoxO). Phosphorylation of FoxO is
regulated by phosphatidylinositol 3′-kinase (PI3K)-dependent
protein kinase B (AKT) activity, which inhibits protein degra-
dation by inhibiting MAFbx/atrogin-1 and MURF-1 expression
and diverts signals for protein synthesis\(^{56–58}\). Atrogin-1/
MAFbx expression is also up-regulated via a p38 mitogen-acti-
ved protein kinase (MAPK)-dependent mechanism in C2C12
myotubes\(^{59}\), while MURF-1 expression is stimulated through
an NF-κB-dependent mechanism\(^{63,65,61}\). Curcumin has been
shown to prevent activation of NF-κB and prevent sepsis-
induced muscle protein degradation\(^{62}\). Furthermore, curcu-
min has been shown to block phosphorylation and subsequent degra-
dation of inhibitor of NF-κB (IκBα)\(^{63}\), which results in an
increase in the rate and extent of muscle regeneration after
trauma\(^{50}\). In contrast to these studies, elevated activity of
NF-κB in mdx mice exhibiting muscular dystrophy was resistant
to dietary curcumin treatment\(^{64}\). The mdx mice have impaired
sarcoplasmic calcium ATPase and depressed p38 MAPK activi-
ties, which suggests the involvement of these enzymes in the
lack of curcumin effect on NF-κB activity\(^{60}\). Curcumin
also has a p38-inhibiting property\(^{65}\), which has been
shown to obstruct p38-mediated TNF-α up-regulation of atro-
gin-1/MAFbx in C2C12 myotubes\(^{59}\). Similarly, the adminis-
tration of curcumin daily for four consecutive days before LPS
injection blunted LPS stimulation of atrogin-1/MAFbx mRNA
expression in mice muscle\(^{35}\); however, these experiments
failed to show curcumin regulation of atrogin-1/MAFbx expres-
sion through mediating AKT activity during LPS stimu-
lation. Based on these data, one could speculate that curcumin
regulates both protein degradation and synthesis pathways
possibly through regulating AKT, NF-κB and/or p38 MAPK
activation. Further experiments are therefore required to address
the molecular effects of curcumin on the regulation of these
cellular mediators.

In conclusion, treatment of cachectic animals bearing
MAC16 tumours with curcumin c3 resulted in the prevention
and reversal of cachexia. Curcumin c3 also attenuated 20S
proteasome activity but its effects on the inhibition of atro-
gin-1/MAFbx and MURF-1 expression are not clear. The
data presented in the present study imply that curcumin c3
may have an effective therapeutic or an adjuvant therapeutic
potential against cachexia.

Acknowledgements

The present study was supported by a grant from Abbott
Nutrition (Abbott Laboratories, Columbus, OH 43215,
USA). The present study does not include any product that
is sold by the sponsor, Abbott Nutrition.
R. A. S., T. D., P. M. and S. DeM. planned and supervised the study. S. H., T. R. and K. A. H. performed in vivo and in vitro experiments. The authors wish to thank Ms Diane Bond for animal care; Ms Charlene Shaffer for secretarial assistance and Dr Karen Spear and Heather Richardson for editing the manuscript.

There is no potential conflict of interest by any of the authors.

References


